Search

Displaying results 4211 - 4220 of 7284 in total
  1. Drug

    Doxepin

    go.drugbank.com/drugs/DB01142
    ApprovedInvestigational

    [T83] In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline … Doxepin is a psychotropic agent with antidepressant and anxiolytic properties.

    Products: DOXEPIN 10 1A PHARMA, DOXEPIN 25 1A PHARMA
  2. Drug

    Sulfacetamide

    go.drugbank.com/drugs/DB00634
    Approved

    An anti-infective agent that is used topically to treat skin infections and orally for urinary tract infections.

    Mixtures: Prascion RA, Prascion RA Cream with Sunscreens
  3. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    [L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).

  4. Drug

    Ranolazine

    go.drugbank.com/drugs/DB00243
    ApprovedInvestigational

    [L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440] … Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities.

  5. Drug

    Diethylstilbestrol

    go.drugbank.com/drugs/DB00255
    ApprovedWithdrawn

    A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. … According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen.

  6. Drug

    Avanafil

    go.drugbank.com/drugs/DB06237
    Approved

    Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. … [L32113] It first received FDA approval on April 27, 2012,[L32058] with subsequent EMA approval in June 2013.[L32113]

  7. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    Cangrelor was approved by the FDA in June 2015 for intravenous application. … An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset

  8. Drug

    Pancrelipase protease

    go.drugbank.com/drugs/DB11066
    ApprovedInvestigational

    [L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion. … Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands.

  9. Drug

    Paltusotine

    go.drugbank.com/drugs/DB16277
    ApprovedInvestigational

    [A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061] … Paltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth

  10. Drug

    Durlobactam

    go.drugbank.com/drugs/DB16704
    ApprovedInvestigational

    [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. … Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases.